Everest Medicines (1952) Stock Overview
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1952 from our risk checks.
1952 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Everest Medicines Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$37.80 |
| 52 Week High | HK$77.55 |
| 52 Week Low | HK$31.70 |
| Beta | 1.8 |
| 1 Month Change | -0.11% |
| 3 Month Change | -0.16% |
| 1 Year Change | -29.41% |
| 3 Year Change | 169.23% |
| 5 Year Change | -53.33% |
| Change since IPO | -48.04% |
Recent News & Updates
Recent updates
Revenues Not Telling The Story For Everest Medicines Limited (HKG:1952)
Jan 21
Everest Medicines Limited's (HKG:1952) Shares Climb 26% But Its Business Is Yet to Catch Up
Jun 12Everest Medicines (HKG:1952) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 01The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%
Apr 08
NRDL Approval And Pipeline Efforts Will Counterbalance Potential Risks
Dependence on NEFECON's success and market strategies in the IgAN space may not deliver the expected revenue, posing financial risks.Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?
Apr 27Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 31A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)
Jan 31Shareholder Returns
| 1952 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 16.2% | 6.7% | -1.3% |
| 1Y | -29.4% | 60.0% | 13.7% |
Return vs Industry: 1952 underperformed the Hong Kong Biotechs industry which returned 60% over the past year.
Return vs Market: 1952 underperformed the Hong Kong Market which returned 13.7% over the past year.
Price Volatility
| 1952 volatility | |
|---|---|
| 1952 Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 1952 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1952's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 722 | Rogers Luo | www.everestmedicines.com |
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases.
Everest Medicines Limited Fundamentals Summary
| 1952 fundamental statistics | |
|---|---|
| Market cap | HK$13.50b |
| Earnings (TTM) | -HK$337.63m |
| Revenue (TTM) | HK$1.94b |
Is 1952 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1952 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.71b |
| Cost of Revenue | CN¥524.82m |
| Gross Profit | CN¥1.18b |
| Other Expenses | CN¥1.48b |
| Earnings | -CN¥297.77m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 69.25% |
| Net Profit Margin | -17.45% |
| Debt/Equity Ratio | 16.3% |
How did 1952 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/30 15:19 |
| End of Day Share Price | 2026/03/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Everest Medicines Limited is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |